

## PRIOR AUTHORIZATION POLICY

**POLICY:** Parkinson's Disease – Ongentys Prior Authorization Policy

- Ongentys® (opicapone capsules – Neurocrine Biosciences)

**REVIEW DATE:** 07/20/2022; selected revision 01/25/2023

---

### OVERVIEW

Ongentys, a peripheral, selective, and reversible catechol-o-methyltransferase inhibitor, is indicated for adjunctive treatment to levodopa/carbidopa in patients with **Parkinson's disease** experiencing "off" episodes.<sup>1</sup>

### Guidelines

The International Parkinson and Movement Disorder Society published an evidence-based review for treatment for motor symptoms of Parkinson's disease (2018).<sup>2</sup> The review categorically divides treatment recommendations by Parkinson's disease characteristics. Ongentys is noted to be efficacious and clinically useful in treatment for motor fluctuations.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Ongentys. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Ongentys as well as the monitoring required for adverse events and long-term efficacy, approval requires Ongentys to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Ongentys is recommended in those who meet the following criteria:

#### FDA-Approved Indication

1. **Parkinson's Disease.** Approve for 1 year if the patient meets all of the following criteria (A and B):
  - A) Patient is currently receiving carbidopa/levodopa therapy; AND
  - B) Ongentys is prescribed by or in consultation with a neurologist.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Ongentys is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

07/20/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**REFERENCES**

1. Ogentys® capsules [prescribing information]. San Diego, CA: Neurocrine Biosciences; May 2020.
2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord.* 2018;33(8):1248-1266.